Higher Non-High-Density Lipoprotein Cholesterol Was Higher Associated With Cardiovascular Disease Comparing Higher LDL-C in Nine Years Follow Up: Cohort Study
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objective: Non-high-density lipoprotein cholesterol (non-HDL-C) may be equivalent to or superior to low-density lipoprotein cholesterol (LDL-C) for the prediction of cardiovascular disease (CVD). However, studies comparing the predictive values of LDL-C and non-HDL-C levels for CVD have yielded conflicting results. In this study, we evaluated the relationship between non-HDL-C, LDL-C, and CVD using a large-scale population dataset from the National Health Information Database (NHID). Methods: We performed a retrospective observational cohort study of 3,866,366 individuals ≥ 20 years, from 2009 to 2018, using the NHID. The participants were divided into LDL-C and non-HDL-C quartiles. The outcome variables included stroke, myocardial infarction (MI), and both. All outcomes were analyzed using Cox proportional hazards regression analysis while controlling for baseline covariates (age, sex, smoking, drinking, regular exercise, body mass index, diabetes, hypertension, and statin use). Results: During 9.1 years of mean follow-up, stroke was diagnosed in 60,081 (1.55%), MI in 31,234 (0.81%), and both stroke and MI in 88,513 (2.29%) participants. Multivariate-adjusted hazard ratios (HRs) for patients in the highest non-HDL-C quartile demonstrated that these patients had a higher risk of stroke (HR, 1.254; 95% confidence interval [CI], 1.224–1.285), MI (HR, 1.918; 95% CI, 1.853–1.986), and both (HR, 1.456; 95% CI, 1.427–1.486) compared with participants in the lowest quartile. These were higher than the HRs for patients in the highest LDL-C quartile for stroke (HR, 1.134; 95% CI, 1.108–1.160), MI (HR, 1.601; 95% CI, 1.551–1.653), and both (HR, 1.281; 95% CI, 1.257–1.306). Conclusion: In our large population study, higher non-HDL-C levels were associated with CVD than LDL-C levels.
Abstract
Objective: Non-high-density lipoprotein cholesterol (non-HDL-C) may be equivalent to or superior to low-density lipoprotein cholesterol (LDL-C) for the prediction of cardiovascular disease (CVD). However, studies comparing the predictive values of LDL-C and non-HDL-C levels for CVD have yielded conflicting results. In this study, we evaluated the relationship between non-HDL-C, LDL-C, and CVD using a large-scale population dataset from the National Health Information Database (NHID). Methods: We performed a retrospective observational cohort study of 3,866,366 individuals ≥ 20 years, from 2009 to 2018, using the NHID. The participants were divided into LDL-C and non-HDL-C quartiles. The outcome variables included stroke, myocardial infarction (MI), and both. All outcomes were analyzed using Cox proportional hazards regression analysis while controlling for baseline covariates (age, sex, smoking, drinking, regular exercise, body mass index, diabetes, hypertension, and statin use). Results: During 9.1 years of mean follow-up, stroke was diagnosed in 60,081 (1.55%), MI in 31,234 (0.81%), and both stroke and MI in 88,513 (2.29%) participants. Multivariate-adjusted hazard ratios (HRs) for patients in the highest non-HDL-C quartile demonstrated that these patients had a higher risk of stroke (HR, 1.254; 95% confidence interval [CI], 1.224–1.285), MI (HR, 1.918; 95% CI, 1.853–1.986), and both (HR, 1.456; 95% CI, 1.427–1.486) compared with participants in the lowest quartile. These were higher than the HRs for patients in the highest LDL-C quartile for stroke (HR, 1.134; 95% CI, 1.108–1.160), MI (HR, 1.601; 95% CI, 1.551–1.653), and both (HR, 1.281; 95% CI, 1.257–1.306). Conclusion: In our large population study, higher non-HDL-C levels were associated with CVD than LDL-C levels.
참고문헌 (20)
- Goldstein JL, "A century of cholesterol and coronaries : from plaques to genes to statins", Cell, 161, pp.161~172 (2015)
- Ference BA, "Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel", Eur Heart J, 38, pp.2459~2472 (2017)
- Mach F, "2019 ESC", EAS guidelines for the management of dyslipidaemias : Lipid modification to reduce cardiovascular risk, 2019, pp.290, 140~205
- 이은정, "2018 Guidelines for the Management of Dyslipidemia in Korea", 지질·동맥경화학회지, 8(2), pp.78~131 (2019), 한국지질동맥경화학회[DOI]
- Arnett DK, "2019 ACC", AHA Guideline on the primary prevention of cardiovascular disease : A report of the american college of cardiology, Circulation, pp.2019, 140[DOI]
- Braunwald E, "Control of residual dyslipidaemic risk", Eur Heart J, 43, pp.3824~3825 (2022)
- Nordestgaard BG, "Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease : new insights from epidemiology, genetics, and biology", Circ Res, 118, pp.547~563 (2016)
- Hegele RA, "The polygenic nature of hypertriglyceridaemia : implications for definition, diagnosis, and management", Lancet Diabetes Endocrinol, 2, pp.655~666 (2014)
- Kamstrup PR, "Genetically elevated lipoprotein(a)and increased risk of myocardial infarction", JAMA, 301, pp.2331~2339 (2009)
- Verbeek R, "Non-high-density lipoprotein cholesterol : current status as cardiovascular marker", Curr Opin Lipidol, 26, pp.502~510 (2015)
- 송선옥, "Background and Data Configuration Process of a Nationwide Population-Based Study Using the Korean National Health Insurance System", Diabetes and Metabolism Journal, 38(5), pp.395~403 (2014), 대한당뇨병학회[DOI]
- Lee J, "Cohort Profile : The National Health Insurance Service-National Sample Cohort(NHIS-NSC), South Korea", Int J Epidemiol, 46, pp.e15~ (2017)
- Levey AS, "A more accurate method to estimate glomerular filtration rate from serum creatinine : a new prediction equation", Ann Intern Med, 130, pp.461~470 (1999)
- Frost PH, "Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program(SHEP)", Circulation, 94, pp.2381~2388 (1996)
- Ridker PM, "Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women", JAMA, 294, pp.326~333 (2005)
- Di Angelantonio E, "Major lipids, apolipoproteins, and risk of vascular disease", JAMA, 302, pp.1993~2000 (2009)
- Sondermeijer BM, "Non-HDL cholesterol vs. apo B for risk of coronary heart disease in healthy individuals : the EPIC-Norfolk prospective population study", Eur J Clin Invest, 43, pp.1009~1015 (2013)
- Boekholdt SM, "Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins : a meta-analysis", JAMA, 307, pp.1302~1309 (2012)
- Grundy SM, "2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
- Trial), "Am J Cardiol", 2013, 506~509